Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era
Gaurav Goyal(Glocal University), Eli L. Diamond(Memorial Sloan Kettering Cancer Center), Augusto Vaglio(Meyer Children's Hospital), Lorenzo Dagna(Vita-Salute San Raffaele University), Mark Heaney(Immunovaccine (Canada)), Fleur Cohen‐Aubart(Inserm), Ronald S. Go(Mayo Clinic), Matthew Collin(Newcastle upon Tyne Hospitals NHS Foundation Trust), André Abdo(Universidade de São Paulo), Benjamin H. Durham(Rutgers, The State University of New Jersey), Xinxin Cao(Shanghai University), Ofer Shpilberg(Texas Oncology), Jennifer Picarsic(University of Pittsburgh), Juvianee Estrada‐Veras(Walter Reed National Military Medical Center), Michael Girschikofsky(Krankenhaus der Elisabethinen), Filip Jankú(The University of Texas MD Anderson Cancer Center), Roei David Mazor(Assuta Medical Center), Eric D. Jacobsen(Dana-Farber Cancer Institute), Oshrat Hershkovitz‐Rokah(Assuta Medical Center), Mineo Kurokawa(University of Tokyo Hospital), Aaron M. Goodman(University of California San Diego), Julien Haroche(Inserm), Paul C. Hendrie(University of Washington), Kazuhiro Toyama(The University of Tokyo), Kenneth L. McClain(Baylor College of Medicine)
Cited by 397
Related Papers
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
|Blood|2016|1.6k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k